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Anticancer effects of 7,8-dihydromethysticin in human leukemia 
cells are mediated via cell-cycle dysregulation, inhibition of cell 
migration and invasion and targeting JAK/STAT pathway
The main focus of this research work was to study the anti-
cancer properties of 7,8-dihydromethysticin against HL-60 
leukemia cells. Investigations were also performed to check 
its impact on the phases of the cell cycle, cell migration and 
invasion, JAK/STAT signalling pathway and intracellular 
mitochondrial membrane potential (MMP) and reactive oxy-
gen species (ROS). Cell proliferation was assessed through 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide (MTT) assay and effects on colony formation were exa-
mined via clonogenic assay. Flow cytometry and Western 
blott analysis were performed to investigate the distribution 
of cell cycle phases. Flow cytometric analysis was performed 
for the examination of MMP and ROS production. The effect 
on JAK/STAT signalling pathway was examined through 
Western blot analysis. Results depicted that 7,8-dihydrome-
thysticin induced concentration- as well as time-dependent 
inhibition of cell proliferation in leukemia HL-60 cells. Clo-
nogenic assay indicated potential suppression in leukemia 
HL-60 cell colonies. The 7,8-dihydromethysticin molecule 
also caused cell cycle arrest at G2/M-phase along with con-
centration-dependent inhibition of cyclin B1, D1 and E. ROS 
and MMP measurements indicated significant ROS enhance-
ment and MMP suppression with increasing 7,8-dihydro-
methysticin concentrations. Additionally, 7,8-dihydro-
methysticin led to remarkable dose-reliant inhibition of cell 
invasion as well as cell migration. Therefore, 7,8-dihydro-
methysticin should be considered a valuable candidate for 
leukemia research and chemoprevention.
Keywords: leukemia, 7,8-dihydromethysticin, flow cytometry, 
cell cycle, signalling pathway
Leukemia is a life-threatening disorder linked to human bone marrow and blood and 
is associated with huge mortality and incidences worldwide (1, 2). The development of this 
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large number of incompletely developed or immature WBCs (3, 4). These immature cells 
divide to create their copies and resist death caused by cellular damage or age. The fre-
quent division of leukemia cells outnumbers the normal RBCs and erythrocytes, thereby 
decreasing the oxygen taking capacity of the blood, fighting infection and bleeding con-
trol. Pathologically and clinically, leukemia is differentiated into various categories based 
on the symptoms, history and effected cell types like lymphoblast and myeloid cells (5, 6). 
Based on this, four different types of leukemia have been identified including acute lym-
phoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphoblastic leuke-
mia (CLL) and chronic myeloid leukemia (CML) (7, 8). ALL and AML are identified with 
higher frequency in children and adults, respectively. Conventional chemotherapeutic 
agents are usually effective against leukemia but the side-effects associated are much more 
serious (9, 10). The overall survival in leukemia patients post-chemotherapy remains very 
low due to the high possibility of disease recurrence and deadly side-effects like cardiac 
events. Thus, there is a pressing need for treatment options for leukemia with reduced 
side-effects and increased overall survival rates. The HL-60 cell line is a type of human 
leukemia cells that has been used in laboratory research on physiology and blood forma-
tion. These cells proliferate in a suspension culture rich in antibiotic chemicals and nutri-
ents. This cell line is derived from patients with acute promyelocytic leukemia and pre-
dominantly exhibit neutrophilic promyelocytic morphology. HL-60 cells are mostly used 
as a cell model to evaluate pharmacological and physiological effects on myeloid differen-
tiation and other aspects. Natural products are comprised of a huge number of chemicals 
that pose no threat to naturally balanced systems in humans and also act as potential 
pharmacological agents (11–15). Naturally occurring Kava plant comprises of different 
chemical entities including kavalactones. One such kavalactone is dihydromethysticin 
(DHM), which has been regarded as a remarkable medicinal and pharmacological agent 
(16). Dihydromethysticin has been reported to exhibit significant activity such as antican-
cer, anticonvulsant, analgesic and anxiolytic and it acts as a monoamine oxidase B rever-
sible inhibitor and positive GABAA receptor allosteric modulator (17–20). The current study 
was designed to unveil the antitumor activity of 7,8-dihydromethysticin in human leuke-
mia HL-60 cells along with examining its effects on cell cycle progression, mitochondrial 
membrane potential (MMP), reactive oxygen species (ROS), inhibition of cell migration 
and invasion and JAK/STAT signalling pathway.
EXPERIMENTAL
Cytotoxicity evaluation
Leukemia HL-60 cells were plated onto 96-well plates and harvested at 75 % of conflu-
ence. Plated cells were exposed to different concentrations of 7,8-dihydromethysticin viz. 
0, 10, 50, 75 and 100 μmol L–1. 7,8-Dihydromethysticin (HPLC purity ≥ 98 %) was procured 
from Shanghai Chemical Reagent Co Ltd, China. The time duration of treatment with the 
currently tested molecule at 37 oC of incubation varied from 24 and 48 h.  Dimethyl 
 sulphoxide (DMSO) vehicle (0.2 %, V/V) was used as a negative control. Cisplatin (Sigma 
Aldrich, China) was used as a reference for the positive control. 7,8-Dihydromethysticin 
treatment was followed by incubation with MTT solution of 0.5 mg mL–1 concentration for 
4 h and 37 oC. The media was completely removed and the extraction of formazan was 
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done in DMSO (200 μL) at room temperature for 10 min. Finally, the optical density (OD) 
was recorded with 570 nm of wavelength and using a microplate reader (BioRad), repeating 
twice in triplicates.
Colony formation assay
Leukemia HL-60 cells were cultured in 6-well plates using RPMI-1640 medium aug-
mented with 10 % fetal bovine serum at a density of 3 × 103 each well. Cultured cells were 
treated with 7,8-dihydromethysticin at variant concentrations of 0, 25, 50 and 100 μmol L–1, 
for one week followed by fixation and staining with 4 % paraformaldehyde and 0.1 % 
crystal violet respectively (Beyotime, China). Utilizing a digital camera, stained cells were 
photographed and analysed (Olympus, Japan).
Cell cycle phase assessment via flow cytometry
Flow cytometric analysis for cell cycle phase distribution was performed to leukemia 
HL-60 cells. These cells were seeded at a density of 1 × 105 cells in each well of 6-well plates. 
Seeding was followed by 7,8-dihydromethysticin treatment at changing concentrations viz. 
0, 25, 50 and 100 μmol L–1 and incubation for 24 h. 7,8-Dihydromethysticin treated cells 
were then phosphate-buffered saline (PBS) washed and fixed in 80 % ethanol and stored 
overnight at 4 oC. Afterward, treated cells were again washed with PBS and subjected to 5 
μg mL–1 RNase and propidium iodide (20 μg mL–1 of PI) staining at 37 oC in a dark room 
for half an hour. Finally, cell cycle analysis was performed with a flow cytometer (FACS-
can; NJ, USA) and DNA content was collected for cell cycle phase distribution with ten 
thousand cells per sample.
ROS and MMP analysis by flow cytometry
Leukemia HL-60 cells were subjected to staining with fluorescent dye tetramethyl-
rhodamine methyl ester (TMRM) and analysing with a flow cytometer for MMP assess-
ment. After treatment with different 7,8-dihydromethysticin concentrations (0, 25, 50 and 
100 μmol L–1) cells were stained in the dark with TMRM (200 μmol L–1) in PBS for about 15 
min at 37 oC. Orange fluorescence intensity was recorded and analysed using flow cyto-
metry. For ROS estimation, leukemia HL-60 cells were harvested from 96-well plates and 
subjected to 7,8-dihydromethysticin treatment at variant concentrations viz. 0, 25, 50 and 
100 μmol L–1. Afterward, cells were washed twice with Hanks’ Balanced Salt Solution 
(HBSS) followed by staining with Dihydroethidium staining (DHE) (100 μL) for half an 
hour at 37 oC. DCF fluorescence with each cell was obtained by capturing, extracting and 
analysis through Data Viewer version 3.0 and ArrayScan II Data Acquisition (Cellomics).
Determination of cell migration through transwell chambers
Transwell chambers (Corning Costar, USA) were used to carry cell migration analysis 
of Leukemia HL-60 cells after 7,8-dihydromethysticin treatment. Briefly, upper chambers 
were filled with media and Leukemia HL-60 cells at a concentration of 2 × 103 cells each 
upper transwell chamber and only the medium was placed in lower chambers for  osmotic 
pressure maintenance. Afterwards, cells were treated with 7,8-dihydromethysticin at 
 variant concentrations viz. 0, 25, 50 and 100 μmol L–1 and incubated for 24 h. Non-migrated 
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cells from upper chambers were discarded using a cotton swab and the fixation of the 
membrane was performed using methanol. Migrated cells were stained with crystal violet 
for 15 min, washed thrice with PBS and captured under a microscope followed by washing 
with 32 % acetic acid. Absorbance was calculated in a plate reader (EnSpire, Perkin Elmer 
Corporation) at 590 nm.
Determination of cell invasion through transwell chambers with Matrigel
The effect of 7,8-dihydromethysticin on cell invasion tendency of Leukemia HL-60 
cells was performed as per the abovementioned procedure except here transwell chambers 
were covered with Matrigel (BD Pharmingen) and Bovine serum-free medium was used.
Western blot analysis for determination of expressions of JAK/STAT signalling 
pathway allied proteins
After treatment of leukemia HL-60 cells with 7,8-dihydromethysticin, cells were har-
vested and lysed using Tris-HCl, sodium dodecyl sulfate (SDS), mercaptoethanol, glycerol 
lysis buffer. Protein content was then separated using sodium dodecyl sulphate polyacryl-
amide gel electrophoresis (SDS-PAGE) and was transferred to hydrophilic polyvinylidene 
fluoride (PVDF) membranes electrophoretically. Afterwards, membranes were treated 
with the antibodies against JAK-1, JAK-2, STAT-1, STAT-2, p-JAK-1, p-JAK-2, p-STAT-1 and 
p-STAT-2 following manufacturer’s guidelines. At 1:1000 dilution ratio, horseradish peroxi-
dase-linked secondary antibodies were introduced and membranes were incubated for 
2 h at room temperature. Membranes were then washed with PBS and visualization of 
immunoreactive bands was done with ECL-PLUS/Kit. β-actin was used for normalization.
Statistical analysis
The experimental data are presented as mean ± standard deviation (SD). Data analysis 
was performed by one-way analysis of variance ANOVA and for multiple comparisons, 
the Student-Newman-Keuls test was used. p < 0.05 was taken to show statistically signifi-
cant differences.
RESULTS AND DISCUSSION
Effect of 7,8-dihydromethysticin treatment on cell viability of leukemia HL-60 cells
Leukemia treatment remains a big challenge for researchers since a higher number of 
side-effects, disease reoccurrence and lower survival present the key drawbacks of cur-
rently accessible treatment modalities. 7,8-Dihydromethysticin has been previously reported 
of inducing antiproliferative effects against different human cancer cells including colorectal 
cancer and osteosarcoma (21, 22). It was also reported to exhibit proapoptotic effects and 
modulated a number of cancer cell survival pathways. Herein, the effects of 7,8-dihydro-
methysticin (Fig. 1a) treatment on cell proliferation of leukemia HL-60 cells were evaluated. 
On increasing the concentrations of 7,8-dihydromethysticin viz. 0, 10, 50, 75 and 100 μmol L–1, 
cell viability decreased remarkably after 24 h and 48 h exposure (Fig. 1b). 7,8-Dihydro-
methysticin exhibited stronger inhibition of cell viability after 48 h time interval as compared 
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to 24 h, thus showing time-dependent inhibition as well. Further, clonogenic assay revealed 
significant inhibitory effects on cell colony formation of HL-60 cells induced by 7,8-dihydro-
methysticin (Fig. 2a). The number of colonies calculated at 0, 25, 50 and 100 μmol L–1 was 
Fig. 1. a) Chemical structure of 7,8-dihydromethysticin; b) MTT viability assay was used for the deter-
mination of cell proliferation. Cisplatin (Sigma Aldrich, Mainland, China) was used as a positive 
control. Results indicated that 7,8-dihydromethysticin treatment in HL-60 cells had induced concen-
tration-dependent cytotoxicity and showed significant results compared to cisplatin. All data are 
represented as mean ± SD and experiments were repeated three times, p < 0.05.
Fig. 2. Clonogenic study of HL-60 cells under a light microscope: a) results showing a decreased 
number of HL-60 cell colonies; b) the number of HL-60 colonies left at indicated concentrations of 
7,8-dihydromethysticin. The data are presented as mean ± SD. *p = 0.05 indicates significant vari-
ances from the control group.
a)                                                     b)
a)                                                                            b)
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260, 225, 125 and 35, respectively (Fig. 2b). Thus, 7,8-dihydromethysticin could induce 
concentration-dependent inhibition of colony formation in leukemia HL-60 cells.
Effect on cell cycle phase distribution
Further, investigations were carried out to check whether the antiproliferative effects 
were associated with cell cycle arrest. From the last two decades, various therapeutic 
targets were recognised and effectively targeted in attaining therapeutic goals. These 
therapeutic targets include cell cycle arrest, ROS enhancement, inhibitory effects on cell 
invasion and migration, apoptosis, autophagy, necrosis and different signalling pathways 
(23–26). Previous studies have reported that 7,8-dihydromethysticin shows significant 
inhibitory effects on cell cycle progression as shown in the induction of G0/G1-phase cell 
cycle arrest in MG-63 osteosarcoma cells (21). Herein, flow cytometric analysis was car-
ried out to unveil the impact of 7,8-dihydromethysticin exposure on cell cycle progression 
in leukemia HL-60 cells. Results revealed a remarkable increase in G2/M-phase cells 
 indicating cell cycle arrest at this phase. After increasing the 7,8-dihydromethysticin 
 concentration viz. 0, 25, 50 and 100 μmol L–1, the percentage of G2/M-phase cells started 
to increase from 14.5, 24.2, 32.1 and 52.3 % respectively (Fig. 3a). Thus, indicating a dose- 
-reliant rise in the number of G2/M-phase cells. Further, Western blot analysis showed 
dose-dependent inhibition of cyclin-B1, cyclin-D1 and cyclin-E expressions (Fig. 3b). 
These Western blot results further validated the cell cycle inhibitory effects of 7,8-dihydro-
methysticin.
Effects on ROS and MMP levels
ROS and MMP play an important role in carcinogenesis as well as its suppression. 
Enhancement of ROS in cancer cells may cause death or any other adverse effects. MMP 
decrease allows the release of cytochrome-C by mitochondria into the cytoplasm giving 
rise to a cascade of reactions that may induce cell death. In most cases, this cell death has 
Fig. 3. Cell cycle analysis via flow cytometry: a) results indicated that 7,8-dihydromethysticin treat-
ment to HL-60 cells induced G2/M-phase cell cycle arrest; b) Western blot assay revealed expression 
of cell cycle allied proteins post 7,8-dihydromethysticin treatment. Results showed inhibition of key 
cell cycle allied proteins (Cyclin-B1, Cyclin-D1 and Cyclin-E) as indicated. All the experiments were 
done in triplicates.
a)                                                                b)
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been shown to be apoptotic cell death (27, 28). ROS levels were estimated via flow cytomet-
ric analysis. Results revealed an incredible increase in the levels of ROS with increasing 
7,8-dihydromethysticin concentration. A concentration-dependent increase in the ROS 
levels was seen as depicted in Fig. 4a. Thus, ROS production increased significantly with 
increased 7,8-dihydromethysticin concentrations. MMP denotes the functioning of mito-
chondria and loss in MMP indicates a loss in mitochondrial function. Herein, MMP analysis 
depicted a remarkable decrease in MMP levels with increasing 7,8-dihydromethysticin 
concentrations exhibiting dose-dependence (Fig. 4b).
Inhibitory effect of 7,8-dihydromethysticin treatment on cell migration and invasion
The metastatic disease often proves more hazardous than a non-metastatic disease, 
because of the far dispersal of the disease from the origin. Therefore, cell migration and 
invasion play a key role in deciding the fate of malignant metastatic cancers. 7,8-Dihydro-
methysticin was previously reported to inhibit cell migration and invasion in human 
colorectal cancer cells via suppression of NLRC3/PI3K signalling (22). Herein, the cell mi-
gration tendency of leukemia HL-60 cells was assessed post-7,8-dihydromethysticin treat-
ment. Results depicted a substantial suppression of cell migration with increased 7,8-dihydro-
methysticin concentrations (Fig. 5a). Transwell chambers coated with Matrigel were 
utilized for the estimation of 7,8-dihydromethysticin treatment on cell invasion tendency 
in leukemia HL-60 cells. It can be seen from the results that the number of invaded cells 
reduced with the increased 7,8-dihydromethysticin concentrations (Fig. 5b). Thus, both 
these complementary assays indicate that the tested molecule has substantial potential to 
inhibit cell invasion as well as cell migration in HL-60 cancer cells.
Effect of 7,8-dihydromethysticin treatment on JAK/STAT signalling pathway
The JAK/STAT pathway (Janus kinase-signal transducer and activator of transcription) 
is a key signalling pathway that transfers signals to the nucleus from membrane receptors. 
Fig. 4. ROS and MMP assessment in leukemia HL-60 cells after 7,8-dihydromethysticin treatment: a) 
ROS production in HL-60 cells was observed to increase after treatment with 7,8-dihydromethysticin 
at indicated concentrations; b) MMP in HL-60 cells was observed to decrease after treatment with 
7,8-dihydromethysticin at indicated concentrations. The data are presented as the mean ± SD. * p < 0.05 
indicates a significant variance from the control group.
a)                                                                        b)
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Fig. 6. Western blot analysis for the determination of effects of 7,8-dihydromethysticin treatment on 
the JAK/STAT signalling pathway in HL-60 leukemia cells. Results indicated inhibition of JAK-1, p-
JAK-1, p-JAK-2, p-STAT-1 and p-STAT-2. Actin was used for normalization.
This pathway is associated with essential growth factors and cytokines, regulating a number 
of cellular events including immune system development and haematopoiesis (29). Herein, 
the effects of 7,8-dihydromethysticin on the JAK/STAT signalling pathway were evaluated. 
The Western blot analysis was performed to study the impact of 7,8-dihydromethysticin 
treatment on JAK/STAT signalling pathway allied proteins. Results revealed that 7,8-dihydro-
methysticin decreased p-JAK-2, p-STAT-1, p-STAT-2 levels and increased STAT-1, STAT-2 
levels (Fig. 6). This indicated 7,8-dihydromethysticin targeted the JAK/STAT signalling 
 pathway hence contributes to its anticancer action.
CONCLUSIONS
Taking together, the abovementioned results indicate that 7,8-dihydromethysticin 
may be a potent antitumor agent against leukemia, as revealed by its inhibitory effects on 
cell cycle, cell migration and invasion as well as targeting JAK/STAT signalling pathway 
and enhancing ROS.
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